Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This study is a retrospective chart review of patients treated with BOTOX® for idiopathic
Overactive Bladder (OAB) as standard of care in clinical practice. The study will determine
the rate of post procedural urinary retention requiring catheterization and identify factors
that may predict urinary retention.
Details
Lead Sponsor:
Allergan
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA